Skip to main content

Response Biomedical CEO Resigns

NEW YORK (GenomeWeb News) – Response Biomedical late Friday announced the resignation of its CEO Wayne Kay, effective immediately. Kay also resigned as a director of the Vancouver, British Columbia-based diagnostics company.

Peter Thompson will serve as executive chairman and interim CEO, and Reponse Bio has retained an executive search firm to seek a permanent CEO.

Kay's resignation came two days after the firm announced a 17 percent increase in its second-quarter revenues. During the quarter, though, its submission to the US Food and Drug Administration for 510(k) clearance of its NTproBNP assay for the diagnosis of heart failure on its Ramp 200 platform had been turned down.

Kay had previously served as CEO of venture capital firm Kleiner Perkins Caufield & Byers, and was president and CEO of Quidel.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.